Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 13, 2023--

Related Keywords

Canada , United States , Peter Dannenbaum , Julie Cunningham , Damini Chokshi , Michael Mcardle , Facebook , Linkedin , European Commission , Merck Co Inc , Statement Of Merck Co Inc , European Union , Twitter , Youtube , Instagram , Merck Research Laboratories , Exchange Commission , European Medicines Agency , Medicinal Products , Human Use , Combined Positive Score , Marjorie Green , Merck Research , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse , Which Can Present With Diabetic , Nervous System , Connective Tissue , Patients With Multiple , Neck Squamous Cell , Bacillus Calmette Guerin Unresponsive , Mismatch Repair Deficient , Mismatch Repair Deficient Colorectal , Looking Statement , Securities Litigation Reform Act , Annual Report , Prescribing Information , Medication Guide , Media Contacts , Business Wire , Region ,